Kymera Therapeutics, Inc. Banner Image

Kymera Therapeutics, Inc.

  • Ticker KYMR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Kymera Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Watertown, Massachusetts
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulatedMore, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
5.0 / 5.0 (1)

Kymera Therapeutics, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.

Kymera Therapeutics, Inc.

Most Recent Annual Report

Kymera Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Kymera Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!